AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Bikunin plus paclitaxel trims tumor burden and ascites in ovarian cancer models.
2004 JUL 1 - (NewsRx.com & NewsRx.net) -- Bikunin plus paclitaxel trims tumor burden and ascites in ovarian cancer models.
According to researchers in Japan, "our previous studies of intraperitoneal ovarian carcinoma in a mouse model demonstrated that bikunin gene transfection could prevent ascites formation and intraperitoneal disseminated metastasis. Although ascites was almost completely inhibited, tumor burden was variably reduced. Several reports have indicated that bikunin may be involved in tumor survival."
"In the present study, the effectiveness of exogenous bikunin and the biodistribution characteristics of [subscript]125I-bikunin were initially examined in a mouse model of human ovarian cancer HRA cells. The once-daily i.p. administration of bikunin significantly decreased progressive growth of HRA tumors and ascites formation in a dose-dependent manner," H. Kobayashi and colleagues, Hamamatsu University, School of Medicine reported.
"Maximal radioisotope tumor uptake peaked at 7.4% injected dose/g at 3 hr. Bikunin binding specificity was demonstrated by reduced tumor uptake after coinjection of excess nonradioactive bikunin. Bikunin was rapidly excreted renally. The bikunin therapy produced the significant inhibition in expression of the proteolysis (uPA and uPAR) and angiogenesis-related molecules (vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF))."
"The second purpose of our study was to optimize the ...
- Bikunin plus paclitaxel trims tumor burden and ascites in ovarian cancer models.
- Newspaper article from: Biotech Week June 30, 2004 700+ words
...Bikunin plus paclitaxel trims tumor...ascites in ovarian cancer models. According...with bikunin plus paclitaxel may be an effective...Cancer (Bikunin plus paclitaxel markedly reduces...mouse model of ovarian cancer. Int J Cancer...
- Neutralizing antibody plus paclitaxel diminish ovarian tumors.
- Newspaper article from: Angiogenesis Weekly December 13, 2002 700+ words
...models of human ovarian cancer in their latest...the VEGF mAb plus paclitaxel and paclitaxel...immunoneutralization plus paclitaxel markedly reduces...mouse model of ovarian cancer. American...inhibitors of VEGF plus paclitaxel may be an effective...
- Neutralizing antibody plus paclitaxel diminish ovarian tumors.(monoclonal...
- Magazine article from: Women's Health Weekly December 12, 2002 700+ words
...models of human ovarian cancer in their latest...the VEGF mAb plus paclitaxel and paclitaxel...immunoneutralization plus paclitaxel markedly reduces...mouse model of ovarian cancer. American...inhibitors of VEGF plus paclitaxel may be an effective...
- New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as...
- Press release article from: PR Newswire June 5, 2007 700+ words
...followed by paclitaxel or doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant...gt;T) (doxorubicin 50 mg/m2 plus paclitaxel 200 mg/m2 repeated every three weeks...chemotherapy regimen in patients with ovarian cancer, primary peritoneal or fallopian...
- Pfizer Discontinues SUN 1094 Trial of Sunitinib plus Paclitaxel in Advanced...
- Newspaper article from: Cancer Weekly June 16, 2009 700+ words
...discontinuation of the SUN 1094 Phase 3 study that evaluated SUTENT® (sunitinib malate) plus paclitaxel versus bevacizumab plus paclitaxel for the first line treatment of patients with advanced breast cancer. The independent Data Monitoring...
- A regimen with low-dose pegylated liposomal doxorubicin plus paclitaxel is...
- Magazine article from: Inpharma Weekly Anonymous August 9, 2008 700+ words
A regimen with low-dose pegylated liposomal doxorubicin plus paclitaxel is active in operable and locally advanced breast cancer, according to a study from Italy. This study included 35 patients who...
- Avastin Used in Combination with Drugs from Bristol-Myers Squibb Has Advantages...
- Press release article from: PR Newswire April 23, 2008 700+ words
...patient share in the ovarian cancer market. Surveyed oncologists...would prescribe Avastin plus paclitaxel/carboplatin to 29 percent...patients with advanced ovarian cancer. As a result, Avastin plus paclitaxel/carboplatin will earn...
- Morphotek[R], Inc. Announces Initiation of Farletuzumab Phase II Study In...
- Press release article from: Business Wire December 2, 2008 700+ words
...with platinum-resistant (PR) ovarian cancer. The randomized, controlled trial will compare farletuzumab plus paclitaxel with a placebo plus paclitaxel...free survival in patients with PR ovarian cancer. Secondary objectives include...
